14 results about "Tuberculosis prevention" patented technology

The invention provides a disease burden prediction and prevention and control decision-making method and system based on machine learning, and relates to the technical field of disease prediction and public health decision-making, and the method comprises the steps: obtaining epidemiological data of tuberculosis and related diseases from an authoritative database, and carrying out the preprocessing of the epidemiological data; respectively training an XGBoost model, an RF (Radio Frequency) model and a Prophet model; training a random forest meta-model by adopting a Stacking fusion strategy, and constructing a hybrid prediction model; calculating RMSE, MAE, MAPE and Rindex evaluation model performance; based on the obtained hybrid prediction model; based on the variable importance analysis result and the prediction result, the influence of the key independent variable on the tuberculosis burden dependent variable is quantified, the effect of the independent variable change on the dependent variable is simulated, and a tuberculosis prevention and control intervention strategy suggestion is generated. By fusing multi-source data and a hybrid modeling technology, tuberculosis prediction precision is remarkably improved, confidence interval quantization and prevention and control strategies are linked for the first time, and data-driven decision support is provided for global tuberculosis prevention and control.

The invention relates to the technical field of biological medicines, in particular to a tuberculosis vaccine antigen and a vaccine. In particular to application of a mycobacterium tuberculosis Rv1787 gene in preparation of a vaccine for preventing and / or treating tuberculosis, in the application, the sequence of the Rv1787 gene or an encoding product thereof is defined, and the Rv1787 gene and the encoding product thereof serve as antigens, have mycobacterium tuberculosis specificity, and can be used for preparing a vaccine for preventing and / or treating tuberculosis. According to the mycobacterium tuberculosis vaccine, identification and response of an organism immune system to mycobacterium tuberculosis can be accurately stimulated, non-specific immune response to other normal tissues is avoided, a brand new and specific molecular target spot is provided for preventing and treating tuberculosis, and the limitation that a traditional vaccine depends on a single antigen or an attenuated strain is broken through. A specific expression product of the gene can stimulate directional recognition and attack of an organism immune system on mycobacterium tuberculosis, the pertinence and effectiveness of vaccines are remarkably improved, and a new path is provided for solving the problem of tuberculosis prevention and treatment.

This invention provides a data storage method and system for tuberculosis detection, relating to the field of tuberculosis detection technology. The data storage method for tuberculosis detection includes the following steps: S1. Collecting whole-genome sequencing data of Mycobacterium tuberculosis, host serum IgG titer, and drug sensitivity test results; S2. Calculating genetic distance D based on a reverse evolution model to generate four-dimensional spatiotemporal coordinates (t, x, y); S3. Performing data partitioning and storage based on the drug target barrier value β; S4. Generating dynamic metadata using a host-pathogen dynamics model and compressing and storing it. This invention implements a dynamic storage entropy adjustment algorithm at the hardware and software collaborative level, continuously optimizing the matching efficiency of data compression and physical storage. This results in an intelligent data hub that can perceive the evolutionary pulse of pathogens and autonomously optimize resources, providing support for clinical tuberculosis prevention and control decisions with temporal depth, spatial correlation, and risk evolution.

The invention relates to the field of vaccines, in particular to application of a bacillus calmette-guerin vaccine and a complete freund's adjuvant in preparation of tuberculosis prevention vaccines. The invention provides a novel inoculation strategy of subcutaneous combined inoculation of the bacillus calmette guerin vaccine and the complete freund's adjuvant, the safety consistent with that of the existing tuberculosis prevention vaccine in the clinical stage is achieved, and the immune protection effect higher than that of the existing tuberculosis prevention vaccine in the clinical stage and the preclinical research stage is achieved. The compound is expected to be used as a novel tuberculosis vaccine for preventing tuberculosis.

The invention provides an intelligent tuberculosis prevention and control method and system based on big data and deep learning, and relates to the technical field of data analysis, and the method comprises the steps: building a patient contact relation network, predicting the tuberculosis transmission risk through a deep neural network model, extracting an infectious index through combining a chest CT image and a sputum bacteria detection result, and obtaining a patient contact relation network; a regional propagation risk map is generated, prevention and control resource configuration is optimized through a Monte Carlo tree search algorithm, accurate prevention and control are achieved, and when an infectious index exceeds a threshold value, a resource configuration scheme is updated in time.

The invention discloses a Mycobacterium tuberculosis epitope mRNA (messenger Ribonucleic Acid) vaccine simulated, predicted and screened by a computer, which is prepared by the following steps: bacterial protein sequence acquisition and signal peptide analysis: acquiring amino acid sequences of proteins ESAT6, CFP10, Ag85A, Ag85B, TB10.4, PPE68, PPE18 and Rv1813c through a database; the method comprises the following steps: analyzing physicochemical properties of proteins, including the number of amino acids, the molecular weight, the instability index and the overall average value of water solubility, analyzing and predicting the allergy of the epitopes by using a server, and generating all potential mutants by using the server to predict and measure the toxicity of the epitopes; the multi-epitope mRNA vaccine candidate is successfully constructed by adopting computer simulation screening and optimization of the mycobacterium tuberculosis multi-epitope antigen, the vaccine design scheme is efficient, controllable and broad-spectrum, a theoretical basis and a candidate construct are provided for early research and development of tuberculosis vaccines, and the vaccine is expected to be used for prevention and control of tuberculosis and has positive influence on public health.

The invention discloses a mycobacterium tuberculosis deletion region protein Rv1577c and a fusion antigen LB28 containing a mycobacterium tuberculosis RD region and a latent infection related antigen, wherein the fusion antigen comprises Rv1577c and Rv1738. The invention provides a candidate antigen Rv1577c of a tuberculosis subunit vaccine through antigen screening and experimental verification. The Rv1577c is deleted in BCG, so that the immunogenicity is better, and the Rv1577c has certain consistency with ESAT6 and CFP10 in bovine tuberculosis immunodiagnosis. And the Rv1577 is combined with a latent infection associated antigen Rv1738 to construct the tuberculosis fusion protein LB28. Under the assistance of an adjuvant DDA + PolyI: C (DP), the fusion protein LB28 shows good immunogenicity in a mouse model, and has an immune protection effect of resisting mycobacterium bovis infection. The Rv1577 and the fusion protein LB28 constructed based on the Rv1577 can be applied to animal and human tuberculosis prevention and treatment.

The invention is applicable to the field of gene engineering, and provides a mycobacterium tuberculosis PPE18-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis PPE18-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis PPE18 protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis PPE18-LS protein nanoparticle is shown as SEQ ID NO: 2 in a sequence table. According to the invention, the key protective antigen PPE18 of mycobacterium tuberculosis and the LS protein with self-assembly characteristic are subjected to fusion expression, and the PPE18-LS protein nanoparticles with uniform structure are successfully prepared through an Escherichia coli expression system. In-vivo experiment results show that the PPE18-LS protein nanoparticles can effectively activate response pathways of humoral immunity and cellular immunity of a host, show obvious protective efficacy in a mouse model, provide an important technical path for developing a new generation of tuberculosis preventive vaccines, and have wide clinical application prospects and industrialization values.

An aspect provides a vaccine composition for preventing tuberculosis comprising chorismate mutase. The vaccine composition alone may induce immunity specific to Mycobacterium tuberculosis, and when provided together with an immune adjuvant, the vaccine composition may induce immunity specific to tuberculosis more effectively. Furthermore, when an existing vaccine for tuberculosis is used as a prime and the vaccine composition according to an aspect including chorismite mutase is provided as a booster, the immunity specific to tuberculosis may be induced significantly more effectively.

The application discloses a fusion protein PP13138R and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, PorB, PADRE and RS-09. The application screens 34 epitopes for Mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and no sensitization, and have the characteristics of high population coverage and the like. The auxiliary peptide PADRE is further added to improve the immunogenicity of the vaccine, and the PorB and RS-09 are added to endow the vaccine with a targeted delivery function. In-vitro experiments prove that the PP13138R can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The PP13138R has the advantages of simple preparation method, low cost, high yield and higher safety as a vaccine. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

The application relates to the technical field of biological medicine, in particular to a tuberculosis vaccine antigen and a vaccine. Specifically, the application provides an application of a mycobacterium tuberculosis Rv1787 gene in preparation of a vaccine for preventing and / or treating tuberculosis, and the application is characterized in that the sequence of the Rv1787 gene or a coded product thereof is determined, wherein the Rv1787 gene and the coded product thereof are used as antigens, have mycobacterium tuberculosis specificity, can precisely stimulate the immune system of the body to recognize and respond to the mycobacterium tuberculosis, avoid non-specific immune reactions to other normal tissues, provide a new specific molecular target for preventing and treating tuberculosis, and break through the limitation of traditional vaccines depending on single antigens or attenuated strains. The specific expression product of the gene can stimulate the immune system of the body to directionally recognize and attack the mycobacterium tuberculosis, significantly improves the pertinence and effectiveness of the vaccine, and provides a new path for solving the tuberculosis prevention and treatment problem.

The application discloses a fusion protein HP13138PB and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, HBD-3, PSM alpha 4 and PADRE. The application screens 34 epitopes for mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and sensitization, and have the characteristics of high population coverage and the like. The immunogenicity of the vaccine is improved by further adding antibacterial peptide HBD-3 and auxiliary peptide PADRE, and PSM alpha 4 is added to endow the vaccine with targeted delivery function. In-vitro experiments prove that HP13138PB can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The HP13138PB as a vaccine has the advantages of simple preparation method, low cost, high yield and higher safety and the like. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

This invention discloses the polypeptide fusion protein CP13138P and its application in tuberculosis prevention. Specifically, it discloses a fusion protein comprising tandem HTL, CTL, and B-cell epitopes, CTB, Pam2Cys, and PADRE. This invention screened 34 epitopes targeting Mycobacterium tuberculosis, which exhibit excellent immunogenicity and antigenicity, are non-toxic and non-sensitizing, and have high population coverage. In vitro experiments demonstrate that CP13138P can stimulate an immune response in human peripheral blood mononuclear cells (PBMCs), increasing IFN-γ in PBMCs. + The number of T lymphocytes is significantly increased, and they secrete significantly high levels of more than a dozen cytokines, including G-CSF, making them a dominant protective antigen. CP13138P, as a vaccine, has advantages such as simple preparation method, low cost, high yield, and enhanced safety. This invention has significant value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

The present invention provides a Mycobacterium tuberculosis transmission relationship detection system and its application, which combines pan-genomics and machine learning algorithms, comprehensively considers multiple genetic differences between strains and epidemiological information between cases, and determines the transmission relationship between cases in a more comprehensive and accurate way. Through sample collection and data preprocessing, genetic differences, epidemiological information, strain pedigree and other characteristics are extracted and integrated and normalized, and then the optimal model is screened out through data partitioning, cluster analysis, multiple algorithm modeling training and evaluation, overcoming the fixed SNP threshold error, comprehensively considering multiple genetic variation types, making full use of epidemiological information, realizing quantitative evaluation of transmission probability, and accurately evaluating the transmission pattern of Mycobacterium tuberculosis, realizing traceability analysis of the transmission path of Mycobacterium tuberculosis, with wide applicability, providing a scientific basis for preventing transmission, improving the efficiency and accuracy of prevention and control, and playing a key role in the global tuberculosis prevention and control process.